Jpmorgan Chase & CO Avita Medical, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Avita Medical, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 23,359 shares of RCEL stock, worth $260,920. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,359
Previous 10,284
127.14%
Holding current value
$260,920
Previous $164,000
12.8%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RCEL
# of Institutions
72Shares Held
6.22MCall Options Held
11.6KPut Options Held
40.1K-
Black Rock Inc. New York, NY1.78MShares$19.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.4MShares$15.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA586KShares$6.55 Million0.0% of portfolio
-
State Street Corp Boston, MA508KShares$5.67 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT267KShares$2.98 Million0.21% of portfolio
About AVITA Medical, Inc.
- Ticker RCEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 25,030,900
- Market Cap $280M
- Description
- AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and prop...